Fig. 5

Endpoint Analysis of Biweekly MnNP Treatment in TBR5 Model. A Treatment schematic for development of TBR5 ovarian tumor model and biweekly MnNP treatment. Serum was collected at endpoint to evaluate circulating levels of (B) AST, (C) ALT, and (D) BUN (n = 5). Changes in (E) ascites volume and (F) tumor weight at endpoint (n = 15, *p < 0.05). G Western blot analysis of cells in the ascites revealed changes in IκBα protein levels (cropped image of western bands). RNA was collected from ascites cells and examined for expression of (H) CXCL9, (I) IL-6, and (J) Arginase-1 (PBS Control n = 4, Scr- and IκBα-MnNP n = 3, *p < 0.05, **p < 0.001). RNA collected from tumor cells was examined for expression of (K) TNF-α and (L) Arginase-1 (n = 5, *p < 0.05, **p < 0.001)